TriSalus Life Sciences
TLSI
36 hedge funds and large institutions have $16.9M invested in TriSalus Life Sciences in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 6 closing their positions.
1,000% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
37% more capital invested
Capital invested by funds: $12.4M → $16.9M (+$4.58M)
20% more funds holding
Funds holding: 30 → 36 (+6)
1.97% more ownership
Funds ownership: 8.09% → 10.06% (+2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$4.33M |
| 2 |
Millennium Management
New York
|
+$281K |
| 3 |
Goldman Sachs
New York
|
+$180K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$142K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$81.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DFO
Duquesne Family Office
New York
|
-$2.14M |
| 2 |
AGC
Angelo Gordon & Co
New York
|
-$54.4K |
| 3 |
EAM
Exos Asset Management
New York
|
-$18.1K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$5.17K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.78K |
TLSI Hedge Fund Activity: Q1 2025 in Review
36 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q1 2025, worth a combined $16.9M — up 37% from $12.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TLSI positions and 6 closed out — a net gain of 6 holders — while 11 added to existing stakes and 1 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $4.33M. The largest seller was Duquesne Family Office, exiting entirely with an estimated $2.14M sold.
- 36 institutional investors held TriSalus Life Sciences (TLSI) as of Q1 2025, up from 30 in Q4 2024.
- Funds reported $16.9M of TriSalus Life Sciences stock for Q1 2025, up 37% quarter-over-quarter.
- 12 funds opened new TriSalus Life Sciences positions in Q1 2025 and 6 closed out, a net change of +6 holders.
- The largest TriSalus Life Sciences buyer in Q1 2025 was Gilder Gagnon Howe & Co, an estimated $4.33M added.
- The largest TriSalus Life Sciences seller in Q1 2025 was Duquesne Family Office, an estimated $2.14M sold.
Based on aggregated 13F filings for Q1 2025.